Literature DB >> 12800962

Use of atypical antipsychotic drugs in patients with dementia.

Charles D Motsinger1, Gregory A Perron, Timothy J Lacy.   

Abstract

Increasingly, atypical antipsychotic drugs are prescribed for elderly patients with symptoms of psychosis and behavioral disturbances. These symptoms often occur in patients with Alzheimer's disease, other dementias, or Parkinson's disease. As the average age of Americans increases, the prevalence of Alzheimer's disease and Parkinson's disease will rise accordingly. Although nonpharmacologic treatments for behavioral disturbances should be tried first, medications often are needed to enable the patient to be adequately cared for. Current guidelines recommend using risperidone and olanzapine to treat psychosis in patients with Alzheimer's dementia. Quetiapine and clozapine are recommended for treatment of psychosis in patients with Parkinson's disease. Additional research is needed for a recently approved agent, ziprasidone. To minimize side effects, these medications should be started at low dosages that are increased incrementally. Drug interactions, especially those involving the cytochrome P450 system, must be considered. Clozapine's potentially lethal side effects limit its use in the primary care setting. Informed use of atypical antipsychotic drugs allows family physicians to greatly improve quality of life in elderly patients with dementia and behavior disturbances.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800962

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  8 in total

Review 1.  Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Authors:  A Gurevich; V Guller; Y N Berner; S Tal
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

2.  Psychotic symptoms in the elderly.

Authors:  Rebecca W Brendel; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

3.  Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study.

Authors:  Rita Moretti; Paola Torre; Rodolfo M Antonello; Tatiana Cattaruzza; Giuseppe Cazzato
Journal:  J Neurol       Date:  2005-04-13       Impact factor: 4.849

4.  Senile Dementia from Neuroscientific and Islamic Perspectives.

Authors:  Mohd Amzari Tumiran; Noor Naemah Abdul Rahman; Rohaida Mohd Saat; Ahmad Zuhdi Ismail; Wan Adriyani Wan Ruzali; Nurul Kabir Nurul Bashar; Durriyyah Sharifah Hasan Adli
Journal:  J Relig Health       Date:  2018-02

5.  A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.

Authors:  Stephanie Kirbach; Kit Simpson; Paul J Nietert; Jacobo Mintzer
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

6.  Long-term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease : results of a 52-week open-label study.

Authors:  Keith Edwards; Barbara Koumaras; Michael Chen; Ibrahim Gunay; Dario Mirski
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 7.  The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use.

Authors:  Ismaeel Yunusa; Marie Line El Helou
Journal:  Front Pharmacol       Date:  2020-05-20       Impact factor: 5.810

8.  Drug Repurposing for Alzheimer's Disease Based on Protein-Protein Interaction Network.

Authors:  Negar Sadat Soleimani Zakeri; Saeid Pashazadeh; Habib MotieGhader
Journal:  Biomed Res Int       Date:  2021-10-14       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.